Takeda 1xbet 카지노armaceutical Co., Ltd.
Otsuka 1xbet 카지노armaceutical Co., Ltd.

• TAKECAB®, discovered by Takeda 1xbet 카지노 disease, is now available in Japan.
• Takeda and Otsuka executed an agreement at the end of March 2014 to co-promote TAKECAB® (1xbet 카지노) in Japan. Under the agreement, the two companies will conduct informational activities for healthcare professionals with the aim of addressing unmet clinical needs in the treatment of acid-related diseases.
• Otsuka will receive from Takeda co-promotion fees based on sales levels of TAKECAB® (in accordance with conditions specified in 1xbet 카지노 agreement).

Takeda 1xbet 카지노armaceutical Company Limited (Head office: Chuo-ku, Osaka; President and COO: Christo1xbet 카지노e Weber; "Takeda") and Otsuka 1xbet 카지노armaceutical Company, Limited (Head office: Chiyoda-ku, Tokyo; President and Representative Director: Tatsuo Higuchi; "Otsuka") announced today that TAKECAB® 10 mg and TAKECAB® 20 mg (generic name: Vonoprazan fumarate, hereafter "TAKECAB"), discovered by Takeda for the treatment of acid-related diseases, is now available in Japan.

TAKECAB, discovered by Takeda, is a new medicine for treating acid-related diseases with a novel mechanism of action called potassium-competitive acid blockers (P-CABs) which competitively inhibits 1xbet 카지노 binding of potassium ions to H⁺,K⁺-ATPase (also known as 1xbet 카지노 proton pump) in 1xbet 카지노 final step of gastric acid secretion in gastric parietal cells. Vonoprazan fumarate has fast-acting, strong and sustained acid secretion inhibitory effects. Takeda and Otsuka executed an agreement at 1xbet 카지노 end of March 2014 to co-promote TAKECAB in Japan.

"Ever since our company launched TAKEPRON® more than two decades ago, we have been supporting patients suffering from acid-related diseases and healthcare professionals who are providing them with treatment," said Masato Iwasaki, 1xbet 카지노.D., Director and President, Japan 1xbet 카지노arma Business Unit of Takeda. "I am delighted that together with Otsuka, an excellent co-promotion partner, we are able to offer a new treatment option to address the unmet medical needs in the gastrointestinal field. Through TAKECAB, we will make further contributions to the treatment of acid-related disease."

"From diagnosis through to treatment Otsuka is contributing broadly in 1xbet 카지노 gastrointestinal field - Mucosta^®is a novel medicine for gastric ulcers and our diagnostic system for helicobacter pylori infections is an excellent complement to it," said Susumu Tamai, Executive Director and Executive Operating Officer, 1xbet 카지노armaceutical Marketing Headquarters of Otsuka. "We are very enthusiastic about entering this collaboration with Takeda in Japan on TAKECAB, an eagerly awaited new treatment for acid-related diseases. We strive to develop innovative medicines and diagnostic drugs to improve the quality of life of many patients."

References